Diagast

Executive Summary

Diagast, founded in 1990 and headquartered in Loos, France, is a specialized in vitro diagnostic (IVD) company focused on transfusion safety through advanced blood typing and immunohematology solutions. The company provides reagents, instruments, and software to blood banks, hospitals, and diagnostic laboratories globally. With a strong presence in Europe and growing international reach, Diagast benefits from its established reputation and regulatory expertise in a market driven by increasing demand for safe blood transfusions and stringent quality standards. The IVD sector is undergoing significant transformation due to the EU's In Vitro Diagnostic Regulation (IVDR), which demands enhanced clinical evidence and post-market surveillance. Diagast is well-positioned to navigate these changes, leveraging its long-standing experience and product portfolio to maintain compliance and capture market share. While the company does not disclose financials, its sustained operations over three decades indicate a stable revenue base and likely profitability. Future growth will depend on successful IVDR certification of its legacy products, expansion into new geographies, and innovation in automated systems.

Upcoming Catalysts (preview)

• Q1 2026IVDR certification of core blood typing product line90% success
• Q2 2026Launch of next-generation automated immunohematology analyzer70% success
• Q3 2026Expansion into Asian market via distribution partnerships60% success